Imricor Medical Systems (ASX:IMR) started the VISABL-VT clinical trial after performing the first-in-human ventricular ablation guided by real-time interventional cardiac magnetic resonance (iCMR) at the Amsterdam University Medical Center, according to a Friday filing with the Australian bourse.
The trial evaluates the safety and effectiveness of radiofrequency ablation of ventricular tachycardia in ischemic cardiomyopathy using the Vision-MR Ablation Catheter 2.0 in the iCMR environment.
The patient was treated for both right-sided and left-sided premature ventricular complexes, the filing said.
Ventricular ablation is a procedure used to treat ventricular tachycardia, a rapid, abnormal heartbeat.
Price (AUD): $1.36, Change: $+0.18, Percent Change: +14.83%
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。